50% off all subscriptions! ... left. Order NowOrder Now

Fate Therapeutics Stock Forecast NASDAQ:FATE

$52.52 (-3.49%)

Volume: 424k

Closed: Nov 26, 2021

Hollow Logo Score: -2.274

Fate Therapeutics Stock Forecast

$52.52 (-3.49%)

Volume: 424k

Closed: Nov 26, 2021

Score Hollow Logo -2.274
Which way will FATE go? Request
Key Stats
P/E Ratio -25.51
Beta 1.83
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 30 and the stock is currently not being overbought or oversold

Fate Therapeutics stock price down 3.49% on Friday
(Updated on Nov 26, 2021)

Sell candidate since 2021-11-10 Loss -7.06%

The Fate Therapeutics stock price fell by -3.49% on the last day (Friday, 26th Nov 2021) from $54.42 to $52.52. During the day the stock fluctuated 7.15% from a day low at $51.44 to a day high of $55.12. The price has fallen in 6 of the last 10 days and is down by -7.03% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -278 thousand shares and in total, 424 thousand shares were bought and sold for approximately $22.28 million.

The stock lies in the lower of a wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $51.60 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -24.39% during the next 3 months and, with a 90% probability hold a price between $39.01 and $43.84 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Tuesday, November 23, 2021, and so far it has risen 0.63%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Fate Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $53.72 and $57.40. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss

Fate Therapeutics finds support from accumulated volume at $52.45 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $3.68 between high and low, or 7.15%. For the last week, the stock has had a daily average volatility of 7.43%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Fate Therapeutics stock A Buy?

Fate Therapeutics holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.274

Predicted Opening Price for Fate Therapeutics of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$53.03 $52.52 (Undervalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 08, 2021 "Citigroup" gave "" rating for FATE. The price target was changed from $60.88 to 0.9%.

Volatility and Risk
Daily Average Volatility: 7.43 %
Overall Risk: Very High High Medium Low Very Low
7.43 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $58.16
Price: $52.52
Support: $52.45

FATE Insider Trading Show all Trades



Last 100 transactions
Buy: 895 487 | Sell: 676 327 (Shares)
Date Action Amount Person Type
Nov 19, 2021 Buy 60 958 Valamehr Bahram Common Stock
Nov 19, 2021 Buy 20 000 Wolchko J Scott Stock Option (right to buy)
Nov 19, 2021 Buy 86 475 Wolchko J Scott Common Stock
Nov 19, 2021 Buy 60 958 Tahl Cindy Common Stock
Nov 19, 2021 Buy 59 540 Dulac Edward J Iii Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 895 487 | Sell: 676 327 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 56.71 7.97 %
55.30 5.29 %
54.43 3.64 %
Current price: 52.52
Support 51.62 -1.71 %
50.75 -3.37 %
49.35 -6.04 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 60.79 15.75 %
59.31 12.93 %
58.16 10.74 %
Current price 52.52
Support 52.45 -0.13%
52.19 -0.63%
0 .

Click to get the best stock tips daily for free!

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. Its novel ex vivo cell programming approach applies to modulate the therapeutic function and direct the fate of immune cells. The company’s lead product candidate is ProTmune, a programmed immuno-regulatory cell therapy that is in clinical development stage for the p... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE